Modality
Small Molecule
MOA
Cl18.2
Target
Cl18.2
Pathway
Tau
PBC
Development Pipeline
Preclinical
~Jul 2023
→ ~Oct 2024
Phase 1
Jan 2025
→ Mar 2028
Phase 1Current
NCT07972263
1,249 pts·PBC
2025-01→2028-03·Terminated
1,249 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-192.0y awayPh2 Data· PBC
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Termina…
Catalysts
Ph2 Data
2028-03-19 · 2.0y away
PBC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07972263 | Phase 1/2 | PBC | Terminated | 1249 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |